v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Revenue    
Revenues $ 26,000,652 $ 36,441,695
Cost of Revenue 13,176,073 15,421,715
Gross profit 12,824,579 21,019,980
Operating expenses    
Sales and marketing 5,989,727 6,067,392
Distribution costs 8,611,702 9,465,149
General and administrative expenses 6,771,937 6,875,575
Share-based compensation 1,169,843 3,664,538
Amortization of acquired intangible assets 2,410,431 2,568,502
Depreciation 1,268,355 913,246
Impairment of long-lived asset - building 336,434 0
Loss on the sale / abandonment of assets in relocation 569,195 0
Impairment of intangible assets and goodwill 7,869,425 3,746,301
Lease impairment, Delray Beach facility 289,969 0
Total operating expenses 35,287,018 33,300,703
Loss from operations (22,462,439) (12,280,723)
Other income (expenses), net    
Change in derivative liability 0 1,770
Other (16,443) 38,344
Interest (expense) income, net (3,124,723) (4,716,274)
Other income (expense), net (3,141,166) (4,676,160)
Loss on operations before income tax (25,603,605) (16,956,883)
Income tax benefit 332,101 3,049,293
Total income tax expense benefit 332,101 3,049,293
Net income (loss) from continuing operations (25,271,504) (13,907,590)
Gain (loss) from the sale of:    
Infusionz and select assets 0 (2,212,542)
Interactive Offers 237,670 0
GainLossFromTheSaleOfVitaMedica 1,948,538 0
E-core (1,737,326) 0
Gain (loss) from the sale of total 448,882 (2,212,542)
Income (loss) on discontinued operations    
Income (loss) on discontinued operations Infuisionz 71,976 (338,418)
Income (loss) on discontinued operations Interactive offers (187,003) (1,729,636)
VitaMedica 213,636 (382,449)
E-core 1,065,575 1,080,379
Income (loss) income from discontinued operations 1,164,184 (1,370,124)
Net loss attributable to non-controlling interest 0 559,967
Net income (loss) attributable to Upexi, Inc. $ (23,658,438) $ (16,930,289)
Basic income (loss) per share:    
Income (loss) per shares from continuing operations $ (24.60) $ (15.56)
(Loss) income per shares from discontinued operations 1.13 (1.53)
Total income (loss) per share attributable to Upexi shareholders basic (23.03) (18.94)
Diluted income (loss) per share:    
Income (loss) per share from continuing operations diluted (24.60) (15.56)
(Loss) income per share from discontinued operations diluted 1.13 (1.53)
Total income (loss) per share attributable to Upexi shareholders diluted $ (23.03) $ (18.94)
Basic weighted average shares outstanding 1,027,232 893,943
Fully diluted weighted average shares outstanding 1,027,232 893,943